Login to Your Account

Financings NEWS

Armed with a $44 million series B, Annexon Biosciences Inc. extended the development runway for its still-preclinical lead asset through completion of phase II programs designed to answer key questions about its pursuit of classical complement pathway inhibitors to treat neurodegenerative disorders.

IFM Therapeutics Inc. closed a $27 million series A financing led by Atlas Venture and Abingworth, with participation from Novartis AG. The Cambridge, Mass.-based company, incubated at Atlas, will use the financing to advance and expand its early stage portfolio of preclinical small-molecule modulators.

Savara Pharmaceuticals Inc. CEO Rob Neville told BioWorld Today the all-stock buyout of Serendex Pharmaceuticals A/S brings aboard a pair of orphan products, one of them "already enrolling phase II/III" trials in Europe and Japan for pulmonary alveolar proteinosis.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: